The FDA cleared C2N Diagnostics' PrecivityAD2 blood test on August 20, 2026 for adults age 40 and older with signs or symptoms of cognitive impairment. For primary care patients, the way to avoid overreading the headline is to seek it only after symptoms and a clinical workup, not as a routine brain-health check. PrecivityAD2 is an Alzheimer's blood test that estimates the likelihood of brain amyloid buildup. It is meant to help an experienced clinician interpret symptoms, not to screen healthy adults or give a stand-alone diagnosis.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from C2N — Use this primary source to verify the official guidance.
- Read the official guidance from Patientcareonline — Use this primary source to verify the official guidance.
Table of Contents
- What the clearance actually covers
- What the blood score is measuring
- Why a non-negative result is not always strong proof
- What to do in a primary care visit
What the clearance actually covers
According to C2N Diagnostics, the test is cleared for adults with cognitive signs or symptoms who are being evaluated for Alzheimer's disease the company announcement. That wording matters.
A headline about approval down to age 40 does not mean adults at age 40 should ask for it without symptoms. The clearance also describes a specific method: high-resolution mass spectrometry with a multiple-analyte calculation. In plain terms, the lab measures more than one blood marker and combines them into one score.
What the blood score is measuring
Patient Care Online reports that the test measures plasma Aβ42/40 and p-tau217 to non-phosphorylated tau217 ratios, then combines them into an Amyloid Probability Score 2 from 0 to 100 its clearance summary. Aβ42/40 reflects amyloid-related protein balance. P-tau217 reflects Alzheimer's-related tau changes.
The score groups patients into result categories tied to amyloid likelihood. A result is therefore a probability aid for the next clinical step. It does not by itself establish Alzheimer's disease or its stage.
Why a non-negative result is not always strong proof
The validation study included 1,142 people and compared blood results with amyloid PET visual reads or spinal-fluid biomarkers. A Positive result had 97.6% positive predictive value, while a Negative result had 93.1% negative predictive value. The middle category needs more caution.
The Neuroscience Education Institute reports that an intermediate "Likely Positive" occurred in 17.3% of validation participants and carried only 77.3% positive predictive value its test-performance summary. So nearly one in five tested people landed in a gray zone. A gray-zone result leaves substantial doubt and often points toward specialist review or confirmatory testing.
What to do in a primary care visit
Start with documented symptoms and an in-person cognitive assessment. The test is cleared only as an aid alongside that professional evaluation, not as a screening test or stand-alone diagnosis.
A doctor experienced in cognitive-impairment evaluation should decide whether blood testing would change referral or follow-up. Bring details that make the visit more useful: Ask what each possible result would change: referral, watchful follow-up, or PET or spinal-fluid confirmation. The FDA-cleared version was expected to become available later in 2026, while the existing laboratory version remained available through the company's clinical laboratory.
- specific memory, language, planning, or navigation changes, with dates
- medicines, sleep problems, depression, hearing loss, and recent illnesses
- family observations about daily tasks, driving, work, and safety
- prior memory scores, brain scans, or lab results, if available
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: A Source-Checked Briefing for Primary Care Patients
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: What Changed and What Comes Next for Primary Care Patients
- The HHS National Alzheimer’s Plan Update for 2026-2035: Questions Spouses and Partners Can Ask a Provider
